Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out?

Al Badarin, Firas J.; Kullo, Iftikhar J.; Kopecky, Stephen L.; Thomas, Randal J.
April 2009
Mayo Clinic Proceedings;Apr2009, Vol. 84 Issue 4, p353
Academic Journal
Ezetimibe is a new lipid-lowering agent that inhibits Intestinal absorption of dietary cholesterol. It substantially lowers low-density lipoprotein cholesterol levels when used alone or in combination with statins. However, its effect on cardiovascular mortality remains unknown. We reviewed peer-reviewed published literature on the effect of ezetimibe on different phases of atherosclerosis. MEDLINE, EMBASE, BIOSIS, and other Web of Knowledge databases were searched for relevant abstracts and articles published in the English language that compared ezetimibe and statins as modulators of atherosclerosis. On the basis of the available evidence, ezetimibe appears to reduce inflammation when used in combination with statins, but its effect on endothelial function is mixed and less clear. The effect of ezetimibe on coronary disease progression or prevention of cardiovascular events Is currently unknown. Use of ezetimibe as a second- or third-line agent to achieve low-density lipoprotein cholesterol treatment goals seems appropriate on the basis of the available evidence.


Related Articles

  • Statins and secondary prevention of coronary heart disease. Ahmed, Mehboub; Griffiths, Peter // British Journal of Community Nursing;April2004, Vol. 9 Issue 4, p160 

    Assesses the effectiveness of lipid-lowering treatments, such as statins, in the secondary prevention of myocardial infarction (MI). Trials demonstrating that statins had a clear and consistent effect in significantly reducing the risk of MI; Approximate decline in MI produced from three trials.

  • Comprehensive lipid-lowering update: Part 2: Who needs lipid-lowering drugs? LaRosa, John C.; McGowan, Mary P.; Weart, C. Wayne // Patient Care for the Nurse Practitioner;Mar2006, Vol. 9 Issue 3, p1 

    The article discusses the use of lipid-lowering drugs in the treatment of coronary heart disease. Statins or other lipid-lowering drugs should be prescribed only in a setting of lifestyle modifications. The choice of a first statin will depend on three main factors: the patient's risk level, the...

  • Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease. Toyama, Kensuke; Sugiyama, Seigo; Oka, Hideki; Iwasaki, Yuri; Sumida, Hitoshi; Tanaka, Tomoko; Tayama, Shinji; Jinnouchi, Hideaki; Ogawa, Hisao // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Objective: Statin- and exercise-therapy are both clinically beneficial by preventing cardiovascular events in patients with coronary artery disease (CAD). However, there is no information on the vascular effects of the combination of statins and exercise on arterial wall stiffness in CAD...

  • Statins and n-3 fatty acids stand out. Russell, John // Patient Care;Jun2005, Vol. 39 Issue 6, p68 

    Focuses on a study on the effect of different antilipidemic agents and diets on mortality. Relative risk for overall mortality of antilipidemic agents such as statins and fibrates compared with control groups; Antilipidemic agents that appear to have the greatest impact on cardiac mortality...

  • Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors. Lopez, Larry M. // American Journal of Health-System Pharmacy;6/15/2002, Vol. 59 Issue 12, p1173 

    Discusses the roles of statins as antilipemic agents for the prevention and management of coronary artery disease. Therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitors; Reduction in total and low-density-lipoprotein cholesterol concentrations; Comparative efficacy of statins;...

  • Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? DeWilde, S.; Carey, I.M.; Bremner, S.A.; Richards, N.; Hilton, S.R.; Cook, D.G. // Heart;Apr2003, Vol. 89 Issue 4, p417 

    Objective: To study trends in the use of lipid lowering drugs in the UK, and to assess which patient factors influence prescribing. Methods: Routinely collected computerised medical data were analysed from 142 general practices across England and Wales that provide data for the Doctors'...

  • Primary Prevention of CHD with Lipid-Lowering Drugs. Walling, Anne D. // American Family Physician;5/15/2001, Vol. 63 Issue 10, p2050 

    Presents an abstract of studies on the use of lipid lowering drugs for preventing coronary heart disease, from the October 21, 2000 issue of the `British Medical Journal.' `Use of Lipid Lowering Drugs for Primary Prevention of Coronary Heart Disease: Meta-Analysis of Randomized Trials,' by M....

  • Early initiation of lipid-lowering therapy improves use in ACS.  // PharmacoEconomics & Outcomes News;4/23/2005, Issue 476, p5 

    Presents the findings of a study on the relation of the early initiation of lipid-lowering therapy at hospital discharge among patients with acute coronary syndromes to patient compliance, conducted by researchers from the U.S. and Great Britain. Number of patients examined for the study;...

  • Impacts of age on coronary atherosclerosis and vascular response to statin therapy. Nozue, Tsuyoshi; Yamamoto, Shingo; Tohyama, Shinichi; Fukui, Kazuki; Umezawa, Shigeo; Onishi, Yuko; Kunishima, Tomoyuki; Sato, Akira; Nozato, Toshihiro; Miyake, Shogo; Takeyama, Youichi; Morino, Yoshihiro; Yamauchi, Takao; Muramatsu, Toshiya; Hirano, Tsutomu; Hibi, Kiyoshi; Terashima, Mitsuyasu; Michishita, Ichiro // Heart & Vessels;Jul2014, Vol. 29 Issue 4, p456 

    Age is a well-established risk factor for cardiovascular disease. Recent trials using intravascular ultrasound (IVUS) have shown that lipid-lowering therapy with statins halts the progression or induces the regression of coronary artery plaques. However, impacts of age on coronary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics